Bill
HB 1139
South Dakota allows terminally ill patients access to investigational treatments not yet approved by the FDA, enabling compassionate use outside standard trial requirements.
HB 1139 permits patients with life-threatening or debilitating diseases to access investigational treatments outside standard clinical trial pathways, commonly known as "Right to Try" legislation. The bill allows individuals to use unapproved drugs, biologics, and medical devices that have completed preliminary safety testing but not final FDA approval.
This legislation directly affects terminally ill patients and their families by potentially expanding access to experimental treatments when conventional options have been exhausted. It reflects a broader national debate about patient autonomy, medical innovation timelines, and the balance between safety oversight and compassionate access to experimental therapies.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
